Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
Arshad M Khanani Sierra Eye Associates, Reno, NV, USA Purpose: To evaluate the durability of fixed bimonthly dosing of intravitreal aflibercept for neovascular age-related macular degeneration.Methods: Records of 16 patients were retrospectively reviewed. Patients received three initial 2.0&nb...
Saved in:
Main Author: | Khanani AM |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/17cb1875a3cc4faa96fe95312818a81e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
by: Thomas M, et al.
Published: (2013) -
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019) -
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
by: Nudleman E, et al.
Published: (2017) -
Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
by: Hahn P
Published: (2014) -
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
by: Tryfon Rotsos, et al.
Published: (2010)